UY32750A - IMIDAZOLS REPLACED AND USE OF THE SAME - Google Patents
IMIDAZOLS REPLACED AND USE OF THE SAMEInfo
- Publication number
- UY32750A UY32750A UY0001032750A UY32750A UY32750A UY 32750 A UY32750 A UY 32750A UY 0001032750 A UY0001032750 A UY 0001032750A UY 32750 A UY32750 A UY 32750A UY 32750 A UY32750 A UY 32750A
- Authority
- UY
- Uruguay
- Prior art keywords
- imidazols
- replaced
- same
- beta
- limited
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de fórmula (I) y sus composiciones farmacéuticas. Además, la presente invención se refiere a métodos terapéuticos para el tratamiento y/o prevención de patologías relacionadas con AB(beta) tales como síndrome de Down, angiopatía B(beta) amiloide tal como pero sin limitarse a angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con el deterioro cognitivo tal como pero sin limitarse a deterioro cognitivo leve (MCI, por su sigla inglés) y enfermedad de Alzheimer.The present invention relates to new compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and / or prevention of diseases related to AB (beta) such as Down syndrome, amyloid B (beta) angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage. , disorders associated with cognitive impairment such as but not limited to mild cognitive impairment (MCI) and Alzheimer's disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22253509P | 2009-07-02 | 2009-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32750A true UY32750A (en) | 2011-01-31 |
Family
ID=43411290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032750A UY32750A (en) | 2009-07-02 | 2010-07-01 | IMIDAZOLS REPLACED AND USE OF THE SAME |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR077365A1 (en) |
TW (1) | TW201103893A (en) |
UY (1) | UY32750A (en) |
WO (1) | WO2011002408A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
US20120165346A1 (en) * | 2010-12-22 | 2012-06-28 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
US9000182B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US10548882B2 (en) * | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
CN114989103B (en) * | 2022-06-09 | 2024-07-09 | 杭州科巢生物科技有限公司 | Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
JP2009520686A (en) * | 2005-11-21 | 2009-05-28 | アストラゼネカ・アクチエボラーグ | Novel 2-amino-imidazol-4-one compounds and their use in the manufacture of a medicament for use in the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia |
TW200831484A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076044A1 (en) * | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
UY31083A1 (en) * | 2007-05-15 | 2009-01-05 | Astrazeneca Ab | SULFOXIMINAL DERIVATIVES FOR THE INHIBITION OF B-SECRETASE |
-
2010
- 2010-07-01 TW TW099121731A patent/TW201103893A/en unknown
- 2010-07-01 UY UY0001032750A patent/UY32750A/en unknown
- 2010-07-01 AR ARP100102352A patent/AR077365A1/en unknown
- 2010-07-02 WO PCT/SE2010/050760 patent/WO2011002408A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201103893A (en) | 2011-02-01 |
WO2011002408A1 (en) | 2011-01-06 |
AR077365A1 (en) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32750A (en) | IMIDAZOLS REPLACED AND USE OF THE SAME | |
UY32751A (en) | IMIDAZOLS REPLACED AND USE OF THE SAME | |
CR20130308A (en) | COMPOUNDS AND ITS USE AS BACE INHIBITORS | |
CR20110255A (en) | NEW COMPOUNDS 578 | |
CO6290683A2 (en) | HETEROCICLIC IMIDAZOLINE PIRIDO COMPOUNDS AND THEIR COMPOSITIONS AS C-MET INHIBITORS | |
GT200900294A (en) | AMINO-HETEROCYCLIC COMPOUNDS | |
ECSP11010754A (en) | USEFUL TRIAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES | |
UY35612A (en) | BICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF SODIUM CHANNELS | |
DOP2012000067A (en) | IMINOTIADIAZINE DIOXIDE COMPOUNDS AS BETA SITE APP DISOCIATION ENZYME INHIBITORS (BACE), COMPOSITIONS, AND ITS USE | |
CL2007001887A1 (en) | COMPOUNDS DERIVED FROM BIFENSUSTUIDAS BY TETRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P2X PURINERGIC RECEPTORS, SUCH AS GASTROINT DISORDERS | |
MX2013004307A (en) | Arylamide derivatives as ttx-s blockers. | |
ECSP13013048A (en) | SPIRO- [1,3] -OXACINES AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS | |
ECSP11011517A (en) | ANTIVIRAL COMPOUNDS | |
CL2008003591A1 (en) | Compounds derived from substituted isoxazolo-pyridine; preparation procedure; pharmaceutical composition; and its use in the treatment of cognitive disorders and Alzheimer's, mediated by binding to the alpha 5-gaba receptor binding site. | |
CR20130588A (en) | HALOGENOALQUIL-1,3-OXAZINAS AS INHIBITORS OF THE BACE1 AND / OR BACE 2 | |
ECSP109904A (en) | ANTIVIRAL COMPOUNDS | |
CR20140071A (en) | NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASA INHIBITORS | |
UY32622A (en) | NEW COMPOUNDS FOR THE TREATMENT OF PATHOLOGIES RELATED TO AB (BETA) | |
ECSP14027564A (en) | AGENTS TO TREAT DISORDERS INVOLVING RIANODINE RECEPTOR MODULATION | |
CL2014001838A1 (en) | Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others. | |
CL2012001461A1 (en) | Compounds derived from diphenyl-pyrazolopyridines, modulators of the nuclear receptor nurr-1; intermediate compounds; pharmaceutical composition; and its use for the treatment and prevention of neurodegenerative diseases, brain trauma, inflammatory diseases, osteoporosis, cancer, among others. | |
ECSP088807A (en) | TETRAHYDRO-PYRIMIDOAZEPINS AS MODULATORS OF THE TRANSITORY POTENTIAL RECEIVER OF VAILLINOID 1 (TRPV1) | |
IN2014MN01982A (en) | ||
DOP2011000134A (en) | WE REACT AS BETA SECRETASA INHIBITORS | |
IN2014MN02056A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DESI | Application deemed to be withdrawn |
Effective date: 20130125 |